Zacks Investment Research downgraded shares of Tonix Pharmaceuticals (TNXP) from OUTPERFORM to NEUTRAL on September 30, 2014, with a target price of $8.00.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Tonix Pharmaceuticals (TNXP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment